Freeline Therapeutics Holdings Plc

NASDAQ FRLN

Data sourced from iex and EODHD
Download Data

Freeline Therapeutics Holdings Plc Income Statement 2017 - 2023

This table shows the Income Statement for Freeline Therapeutics Holdings Plc going from 2017 until 2023. The income statement, also known as the profit and loss statement, is a financial statement that provides a summary of a company's revenues, expenses, and net income over a specific period (such as a quarter or a year). It shows the company's ability to generate revenue, manage expenses, and ultimately determine its profitability.
Income Statement Trend Unit 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-06-30 2019-03-31 2018-12-31 2018-06-30 2018-03-31 2017-12-31
Revenue
M 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 - - - - - -
Cost of Revenue
M 0 0 0 - - - - - - - - - - - - - - - - - -
Gross Profit
M 0 0 0 - - - - - - - - - - - - - - - - - -
Operating Expenses
M 12 16 20 - - - - - - - - - - - - - - - - - -
Selling, General, and Administrative Expenses (SG&A)
M 6 9 6 6 9 8 8 7 13 15 10 11 3 8 4 4 4 4 2 2 2
Research and Development (R&D) Expenses
M 6 9 13 13 15 19 20 25 23 24 24 21 26 12 17 12 12 12 9 9 9
Other Operating Expenses
M 0 -2 1 - - - - - - - - - - - - - - - - - -
Costs and Expenses
M 12 18 18 - - - - - - - - - - - - - - - - - -
Operating Income
M -12 -16 -20 -20 -24 -27 -28 -34 -35 -39 -34 -32 -29 -20 -21 -16 -16 -16 -10 -10 -10
Interest Expense
M - - 6 6 0 0 1 0 0 - - 0 0 - - - - - - - -
Non-operating Income/Expense
M 0 1 -3 -3 9 3 1 -3 4 -2 -2 -10 0 0 1 2 2 -2 2 2 -2
EBT
M -12 -16 -23 -23 -15 -24 -27 -34 -31 -40 -35 -38 -25 -17 -17 -13 -13 -13 -8 -8 -8
Income Tax Provision
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Income after Tax
M -12 -16 -23 -23 -15 -24 -27 -35 -31 -40 -35 -38 -25 -17 -17 -13 -13 -13 -8 -8 -8
Non-Controlling Interest
M - 0 0 0 0 0 0 0 0 0 0 -7 0 0 0 - - - - - -
Net Income
M - -16 1 -23 -15 -24 -27 -35 -31 -40 -35 -32 -25 -17 -17 -12 -12 - - - -
Shares (Basic, Weighted)
M - - - - - - - - - - - - - - - - - - - - -
Shares (Diluted, Weighted)
R 4,358,043.00 4,343,317.00 4,328,810.00 59,271,778,000.00 4,332,041.00 4,302,000.00 2,842,956.00 2,383,815.00 2,381,560.00 2,378,760.00 2,377,030.00 2,390,329.00 2,316,312.00 2,287,249.00 423,188.00 21,351,152.00 21,351,152.00 21,351,152.00 21,351,152.00 21,351,152.00 21,351,152.00
EBITDA
M -12 -19 -16 -16 -23 -26 -27 -31 -34 -38 -33 -28 -24 -16 -17 -13 -13 -16 -8 -8 -10
Depreciation and Amortization
M 0 0 4 4 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
EBIT
M -12 -20 -20 -20 -24 -27 -28 -31 -35 -38 -33 -28 -25 -17 -17 -13 -13 -16 -8 -8 -10
Income from Discontinued Operations
M - - - - - - - - - - - - - - - - - - - - -
Tax Rate (Effective)
% -0.34 -0.04 -1.20 -1.20 -0.34 -0.10 -0.08 -0.91 -0.04 -0.02 -0.03 -0.14 -0.30 0.78 -0.79 -0.26 -0.26 -0.26 -0.08 -0.08 -0.08
Earnings Per Share (EPS), Basic
M - - - - - - - - - - - - - - - - - - - - -
Earnings Per Share (EPS), Diluted
M - 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 - - - -
Gross Profit Margin
% -7,575.18 29.60 - - - - - - - - - - - - - - - - - - -
Operating Income Margin
% -245,320.00 -2,536.63 - - - - - - - - - - - - - - - - - - -
Net Income Margin
% - -2,594.98 - - - - - - - - - - - - - - - - - - -
EBITDA Ratio
% -231,180.00 -3,099.68 - - - - - - - - - - - - - - - - - - -
EBIT Ratio
% -238,900.00 -3,169.85 - - - - - - - - - - - - - - - - - - -
EBT Ratio
% -240,940.00 -2,594.00 - - - - - - - - - - - - - - - - - - -

StockViz Staff

September 19, 2024

Any question? Send us an email